Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects

Oncogene

Volumn 27, Issue 15, 2008, Pages 2208-2214

  Perazzona, B ^a   Lin, H ^a   Sun, T ^a   Wang, Y ^a   Arlinghaus, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BCR kinase defective BCR; BCR ABL; CML

Indexed keywords

AGAR; BCR ABL PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; PHOSPHOTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL CLONE; CELL DISRUPTION; CELL MUTANT; CHRONIC MYELOID LEUKEMIA; COLONY FORMING CELL; ENZYME ACTIVITY; GENE OVEREXPRESSION; MOUSE; NONHUMAN; NUDE MOUSE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; SOLID TUMOR; TUMOR VOLUME;

ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FUSION PROTEINS, BCR-ABL; GENES, MYC; HUMANS; MICE; MICE, NUDE; MUTANT PROTEINS; PHOSPHOTRANSFERASES; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCR; TRANSFECTION; TUMOR STEM CELL ASSAY;

MUS MUSCULUS;

EID: 41649100100     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210851     Document Type: Article

References (23)

1. Abe J, Kusuhara M, Ulevitch RJ, Berk BC, Lee JD. (1996). Big mitogenactivated protein kinase 1 (BMK1) is a redox-sensitive kinase. J Biol Chem 271: 16586-16590.
2. Arlinghaus RB. (2002). BCR: a negative regulator of the Bcr-Abl oncoprotein in leukemia. Oncogene 21: 8560-8567.
3. Daley GQ, Baltimore D. (1988). Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci USA 85: 9312-9316.
4. Guo JQ, Lian JY, Xian YM, Lee M-S, Deisseroth AB, Stass SA et al. (1994). BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 83: 3629-3637.
5. Hawk N, Sun T, Xie S, Wang Y, Wu Y, Liu J et al. (2002). Inhibition of the BCR-ABL oncoprotein by BCR requires phosphotyrosine 354. Cancer Res 62: 386-390.
6. Klucher KM, Lopez DV, Daley GQ. (1998). Secondary mutation maintains the trasnformation state in BaF3 cells with inducible BCR-ABL expression. Blood 91: 3927-3934.
7. Li WJ, Dreazan O, Kloetzer W, Gale RP, Arlinghaus RB. (1989). Characterization of the bcr gene products in hematopoietic cells. Oncogene 4: 127-138.
8. Lin F, Monaco G, Sun T, Liu J, Lin H, Stephens C et al. (2001). BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model. Oncogene 20: 1873-1881.
9. Ling X, Ma G, Sun T, Liu J, Arlinghaus RB. (2003). Bcr and Abl interaction. Oncogenic activation of c-Abl by sequestering Bcr. Cancer Res 63: 298-303.
10. Liu J, Campbell M, Guo JQ, Lu D, Xian YM, Anderson BS et al. (1993). BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon. Oncogene 1: 101-109.
11. Liu J, Wu Y, Ma GZ, Lu D, Haataja L, Heisterkamp N et al. (1996). Inhibition of BCR serine kinase by tyrosine phosphorylation. Mol Cell Biol 3: 998-1005.
12. Lu D, Liu J, Campbell M, Guo JQ, Heisterkamp N, Groffen J et al. (1993). Tyrosine phosphorylation of P160 BCR by P210 BCR-ABL. Blood 82: 1257-1263.
13. Mahon GM, Wang Y, Korus M, Kostenko E, Cheng L, Sun T et al. (2003). The c-Myc oncoprotein interacts with Bcr. Curr Biol 5: 437-441.
14. Maru Y, Witte ON. (1991). The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell 67: 459-468.
15. McWhirter JR, Galasso DL, Wang JY. (1993). A coiled-coil oligomerization domain of BCR is essential for the transforming function of BCR-ABL oncoproteins. Mol Cell Biol 13: 7587-7595.
16. Moravcová J, Regner J, Moučková D, Fišer K, Zmeková V, Maláčová R et al. (2005). Disease status in patients with chronic myeloid leukemia is better characterized by BCR-ABL/BCR transcript ratio than by BCR-ABL transcript level, which may suggest a role for normal BCR gene in the disease pathogenesis. Neoplasma 52: 119-125.
17. Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G et al. (2006). Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell 21: 787-798.
18. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. (1991). BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66: 161-171.
19. Ress A, Moelling K. (2005). Bcr is a negative regulator of the Wnt signaling pathway. EMBO Rep 11: 1095-1100.
20. Sawyers CL, Callahan W, Witte ON. (1992). Dominant negative MYC blocks transformation of ABL oncogenes. Cell 70: 901-910.
21. Stam K, Heisterkamp N, Reynolds Jr FH, Groffen J. (1987). Evidence that the phl gene encodes a 160 000-dalton phosphoprotein with associated kinase activity. Mol Cell Biol 5: 1955-1960.
22. Wu Y, Ma G, Lu D, Lin F, Xu HJ, Liu J et al. (1999). BCR: a negative regulator of the Bcr-Abl oncoprotein. Oncogene 18: 4416-4424.
23. Xie S, Lin H, Sun T, Arlinghaus RB. (2002). Jak2 is involved in c-Myc induction of Bcr-Abl. Oncogene 21: 7137-7146.